Clinical Trial Update: The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1 [Phase 3]

View source ↗

Summary

The update reports results from the Efavirenz CNS exposure sub-study of the Encore1 Phase 3 trial in HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Kirby Institute | Conditions: HIV Infection | Phase 3 | Status: COMPLETED